Core Diagnostics
Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $29.1m Valuation: $29.1m | Acquisition | |
| Total Funding | 000k | ||
Related Content
CORE Diagnostics operates in the healthcare sector, specializing in advanced diagnostic solutions for hereditary and sporadic cancers, kidney diseases, and reproductive health. The company serves a diverse clientele, including hospitals, research centers, and individual patients. CORE Diagnostics leverages cutting-edge technologies such as liquid biopsies, ddPCR, PCR, rtPCR, qPCR, NGS, and Sanger Sequencing to provide precise and early diagnosis. The business model revolves around offering high-quality diagnostic tests and services, which are trusted by over 3,000 doctors and have impacted 170,000 patient lives. Revenue is generated through partnerships with pharmaceutical companies, healthcare institutions, and direct patient services. The company is based in Gurgaon, Haryana, and is recognized for its comprehensive biopsy reports and automated cytogenetics and cytopathology platforms. CORE Diagnostics aims to enhance diagnostic confidence and reduce the need for retesting by providing detailed images and adhering to global reporting guidelines.
Keywords: advanced diagnostics, hereditary cancers, sporadic cancers, kidney diseases, reproductive health, liquid biopsies, molecular biology, cytogenetics, cytopathology, healthcare innovation.